DS5 vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- Estimated 30-60 minutes (peptide degradation)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200-500 mcg per dose
- 10 mg per day
- Frequency
- Once nightly
- Daily for 10–30 days
- Key Benefits
- Promotes delta-wave (deep) sleep and improves sleep quality
- May reduce sleep onset latency
- HPA axis modulation for stress reduction
- Non-addictive sleep support without tolerance development
- Potential circadian rhythm normalization
- Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Generally well-tolerated in research subjects
- Possible morning grogginess at higher doses
- Mild blood pressure fluctuations reported with DSIP
- Limited human safety data for DS5 specifically
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —